Recent findings further highlight that esketamine, at a clinical dose, can inhibit the Akt signaling pathway, promote microglial M2 polarization, and enhance autophagy, ultimately reducing cerebral ischemia/reperfusion injury [164]. The gene discussed is AKT1; the disease is Cerebral ischemia.